Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a history of OAB for at least 3 months prior to the Screening Visit.~2. Meets either the OAB Wet or OAB Dry criteria.~Exclusion Criteria:~Urology Medical History~1. Patient had an average total daily urine volume \> 3000 mL in the past 6 months or during the 14-day Run-in Period.~2. Has lower urinary tract pathology that could, in the opinion of the Investigator, be responsible for urgency, frequency, or incontinence.~3. Has a history of surgery to correct stress urinary incontinence, pelvic organ prolapse, or procedural treatments for BPH within 6 months of Screening.~4. Has current history or evidence of Stage 2 or greater pelvic organ prolapse (prolapse extends beyond the hymenal ring).~5. Patient is currently using a pessary for the treatment of pelvic organ prolapse.~6. Has a known history of elevated post-void residual volume defined as greater than 150 mL.~7. Has undergone bladder training or electrostimulation within 28 days prior to Screening or plans to initiate either during the study.~8. Has an active or recurrent (\> 3 episodes per year) urinary tract infection by clinical symptoms or pre-defined laboratory criteria.~9. Has a requirement for an indwelling catheter or intermittent catheterization.~10. Has received an intradetrusor injection of botulinum toxin within 9 months prior to Screening.~11. Has uncontrolled hyperglycemia (defined as fasting blood glucose \> 150 mg/dL or 8.33 mmol/L and/or non-fasting blood glucose \> 200 mg/dL or 11.1 mmol/L) or, if in the opinion of the Investigator, is uncontrolled.~12. Has evidence of diabetes insipidus.~13. Is pregnant, breast-feeding, or is planning to conceive within the projected duration of the study.~14. Has a concurrent malignancy or history of any malignancy within 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.~15. Has uncontrolled hypertension (systolic blood pressure of ≥ 180 mmHg and/or diastolic blood pressure of ≥ 100 mmHg) or has a resting heart rate (by pulse) \> 100 beats per minute.~16. Has narrow angle glaucoma (primary open angle glaucoma is not excluded).~17. Has a history of cerebral vascular accident, transient ischemic attack, unstable angina, myocardial infarction, coronary artery interventions (e.g., coronary artery bypass grafting or percutaneous coronary interventions \[e.g., angioplasty, stent insertion\]), or neurovascular interventions (e.g., carotid artery stenting) within 6 months prior to the Screening Visit. Has a known history of liver disease.~18. Has a history of injury, surgery, or neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's) that could affect the lower urinary tract or its nerve supply.~19. Has hematuria, including microscopic hematuria according to pre-defined criteria.~20. Has clinically significant electrocardiogram (ECG) abnormality.~21. Has alanine aminotransferase or aspartate aminotransferase \> 2.0 times the upper limit of normal (ULN), or bilirubin (total bilirubin) \> 1.5 x ULN (or \> 2.0 x ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome).~22. Has an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2.~23. Has an allergy, intolerance, or a history of a significant clinical or laboratory adverse experience associated with any of the active or inactive components of the vibegron formulation or tolterodine formulation.~24. Is currently participating or has participated in a study with an investigational compound or device within 28 days prior to signing informed consent, or has participated in any previous study with vibegron.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vibegron + Placebo to match Tolterodine (Type: EXPERIMENTAL): None
- Placebo to match vibegron + Placebo to match Tolterodine (Type: PLACEBO_COMPARATOR): None
- Tolterodine + Placebo to match vibegron (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).